التفاصيل البيبلوغرافية
| العنوان: |
Effect of cladribine on COVID-19 serology responses following two doses of the BNT162b2 mRNA vaccine in patients with multiple sclerosis. |
| المؤلفون: |
Brill, Livnat, Rechtman, Ariel, Zveik, Omri, Haham, Nitzan, Levin, Netta, Shifrin, Alla, Rozenberg, Ayal, Vaknin-Dembinsky, Adi |
| المصدر: |
Multiple Sclerosis & Related Disorders; Jan2022, Vol. 57, pN.PAG-N.PAG, 1p |
| مستخلص: |
• Cladribine-treated MS patients produce antibodies to the SARS-CoV-2 mRNA vaccine. • Cladribine-treated, untreated-MS patients and HCs had 100% serology response. • There is no correlation between lymphocytes count and SARS-CoV-2 IgG levels. multiple sclerosis (MS) patients are treated with immunomodulatory treatments that can influence their ability to develop a protective antibody response to the SARS-CoV-2 vaccine. Vaccine efficacy is important for treatment decision and for patients' reassurance. The main objective is to assess antibody response to SARS-CoV-2 vaccine in MS patients treated with cladribine. Serology response was tested in 97 participants, 67 MS patients and 30 healthy controls (HCs), using two independent methods, 2–3 weeks following the second dose of the BNT162b2 vaccine. HCs (n = 30) and MS patients treated with cladribine (n = 32) had 100% positive serology response against the SARS-CoV-2 spike protein following the second vaccine dose (mean S1/S2-IgG and RBD-IgG:284.5 ± 104.9, 13,041±9411 AU/mL and 226.3 ± 121.4, 10,554±11,405 AU/mL respectively). Comparable findings were observed for untreated MS patients, and interferon beta-1a-treated MS patients (mean S1/S2-IgG: 282.1 ± 100.1, 276.9 ± 94.31 AU/mL respectively). No correlation was found between lymphocyte counts, treatment duration, or time between cladribine dose and vaccination, and serology response or antibody titers. Cladribine treated MS patients are able to produce antibodies to the SARS-CoV-2 mRNA vaccine. In the era of the COVID-19 pandemic, it is reassuring and important for both patients and physicians and will allow to develop consensus guidelines. [ABSTRACT FROM AUTHOR] |
|
Copyright of Multiple Sclerosis & Related Disorders is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Supplemental Index |
